Rose Hart

Rose Hart

Auto-generated profile, based on publicly available information

Rose Hart

Lumanity, Sheffield, UK

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2020 in PharmacoEconomics
Verified
Journal Article
Closed access
PDF file
RHRose Hart
Rose Hart
DBDarren Burns
Darren Burns
BRBram Ramaekers
Bram Ramaekers
SRShijie Ren
Shijie Ren
DGDaniel Gladwell
Daniel Gladwell
DLDawn Lee
Dawn Lee

1 June 2020 in PharmacoEconomics - Open
Verified
Journal Article
Open access
PDF file
RBRachael Batteson
Rachael Batteson
RHRose Hart
Rose Hart
MHMatthew Hemstock
Matthew Hemstock
KGKyna Gooden
Kyna Gooden
SKSrividya Kotapati
Srividya Kotapati
AAAdenike Amadi
Adenike Amadi
Nivolumab demonstrated significant recurrence-free survival (RFS) gains versus ipilimumab in the CheckMate-238 trial, whereas the CA184-029 trial showed superior RFS gains for ipilimumab versus placebo. No head-to-head trial data were available to compare the efficacy of nivolumab to that of observation, so indirect treatment comparisons were required. Additionally, overall survival (OS) data were not available from CheckMate-238, and the clinical pathway for melanoma has changed significantly over the last decade. Four modelling options were developed using different methods and evidence sources to estimate OS and the impact of nivolumab on predicted life-years in the adjuvant setting; however, this article focuses on two primary methods.

30 March 2024 in Advances in Therapy
Verified
Journal Article
Open access
PDF file
RHRose J. Hart
Rose J. Hart
FHFareen Hassan
Fareen Hassan
SASarah Alulis
Sarah Alulis
KPKarl W. Patterson
Karl W. Patterson
JBJennifer Norma Barthelmes
Jennifer Norma Barthelmes
DLDawn Lee
Dawn Lee
Introduction For some immune-mediated disorders, despite the range of therapies available there is limited evidence on which treatment sequences are best for patients and healthcare systems. We investigated how their selection can impact outcomes in an Italian setting. Methods A 3-year state-transition treatment-sequencing model calculated potential effectiveness improvements and budget reallocation considerations associated with implementing optimal sequences in ankylosing spondylitis (AS), Crohn’s disease (CD), non-radiographic axial spondyloarthritis (NR-AxSpA), plaque psoriasis (PsO), psoriatic arthritis (PsA), rheumatoid arthritis (RA), and ulcerative colitis (UC). Sequences included three biological or disease-modifying treatments, followed by best supportive care. Disease-specific response measures were selected on the basis of clinical relevance, data availability, and data quality. Efficacy was differentiated between biologic-naïve and experienced populations, where possible, using published network meta-analyses and real-world data. All possible treatment sequences, based on reimbursement as of December 2022 in Italy (analyses’ base country), were simulated. Results Sequences with the best outcomes consistently employed the most efficacious therapies earlier in the treatment pathway. Improvements to prescribing practice are possible in all diseases; however, most notable was UC, where the per-patient 3-year average treatment failure was 37.3% higher than optimal. The results focused on the three most crowded and prevalent immunological sub-condition diseases in dermatology, rheumatology, and gastroenterology: PsO, RA, and UC, respectively. By prescribing from within the top 20% of the most efficacious sequences, the model found a 15.1% reduction in treatment failures, with a 1.59% increase in drug costs. Conclusions Prescribing more efficacious treatments earlier provides a greater opportunity to improve patient outcomes and minimizes treatment failures.

25 September 2024 in Applied Health Economics and Health Policy
Verified
Journal Article
Closed access
PDF file
DLDawn Lee
Dawn Lee
RHRose Hart
Rose Hart
DBDarren Burns
Darren Burns
GMGrant McCarthy
Grant McCarthy